Insider Buying Activity Uncovered - 7 Stocks On The Rise

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Musk: My new robots could be bigger than Tesla]( No one can deny Elon Musk is a visionary. But has he finally gone too far? [>>See the shocking future of AI here<<]( --------------------------------------------------------------- December 28, 2023 Editorial Insights Insider trading occurs when company executives or major shareholders trade stocks based on non-public information. Monitoring these trades provides insight into insiders' expectations for the company's future. For instance, significant purchases before public announcements may indicate anticipated positive news and a potential share price increase. Note: "Insider Buying" is legal stock purchasing by company directors or officers, distinct from illegal insider trading based on non-public information. It's not a crime when based on public information. Insiders, having unique insights, often buy shares when they believe the stock is undervalued. This report lists stocks recently identified with substantial insider buying. --------------------------------------------------------------- Sponsor Message [Rare Chance to Be an Early Investor in AI Energy Breakthrough]( expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors. [Just go here for full details.]( --------------------------------------------------------------- [Verrica Pharmaceuticals]( Ticker: [VRCA]( Recent Price: $7.15 Average Analyst Price Target: $11.80 (71.33%) Market Cap: $273.42M Role Transaction Description No. of Shares Amount Date >10% Owner Informative Buy Non Open Market Buy 504,652 $3,256,191 3 Days Ago Recent Analyst Action: Oren Livnat, analyst at H.C. Wainwright, reiterates coverage on [Verrica Pharmaceuticals (VRCA)]( in the Healthcare sector with a Buy rating and a price target of $12 (1 month ago). Here are 3rd party ratings for [VRCA](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Sell, Top 30% (76 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [This New Tech Could Be Worth THREE TIMES the Entire New York Stock Exchange...]( believe this new tech will create more wealth than all the fortunes of the last 150 years combined. That’s why the world’s richest men and even the United States Senate approved throwing hundreds of BILLIONS of dollars into this new technology… [And right now, there’s a little-known stock at the center of all the action.]( In fact, this small-cap stock is still trading for less than it costs to buy a tank of gas. [Click here now for the whole story.]( --------------------------------------------------------------- [HighPeak Energy]( Ticker: [HPK]( Recent Price: $15.07 Average Analyst Price Target: $23.07 (-33.64%) Market Cap: $1.89B Role Transaction Description No. of Shares Amount Date CEO,Director, >10% Owner Informative Buy Non Open Market Buy 150,442 $2,162,268 3 Days Ago Recent Analyst Action: Neal Dingmann, analyst at Truist Financial, reiterates coverage on [HighPeak Energy (HPK)]( in the Energy sector with a Sell rating and a price target of $10 (1 month ago). Here are 3rd party ratings for [HPK](: - TipRanks.com: Moderate Sell - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Bottom 19% (205 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Lemaitre Vascular]( Ticker: [LMAT]( Recent Price: $57.67 Average Analyst Price Target: $64.20 (11.32%) Market Cap: $1.28B Role Transaction Description No. of Shares Amount Date Chairman & CEO, >10% Owner Informative Buy Options Exercised and fully kept 16,446 $597,687 2 Days Ago Recent Analyst Action: Rick Wise, analyst at Stifel Nicolaus, reiterates coverage on [Lemaitre Vascular (LMAT)]( in the Healthcare sector with a Hold rating and a price target of $50 (1 month ago). Here are 3rd party ratings for [LMAT](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Bottom 36% (162 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The #1 Threat to Your Wealth in 2024]( predicted the Lehman Brothers collapse, Bitcoin's 2018 crash, and the Nasdaq's top in 2021. Now Dan Ferris is issuing an urgent new warning... A new AI threat expected cost Americans $100 billion in the next 18 months... even if you don't own a single AI stock you could still be a victim just by picking up the phone. Learn how to protect yourself immediately,[right here.]( --------------------------------------------------------------- [Moleculin Biotech]( Ticker: [MBRX]( Recent Price: $0.71 Average Analyst Price Target: $7.33 (322.54%) Market Cap: $19.31M Role Transaction Description No. of Shares Amount Date CFO Informative Buy Non Open Market Buy 28,986 $20,000 2 Days Ago CEO & President, Director Informative Buy Non Open Market Buy 188,404 $129,999 2 Days Ago Director Informative Buy Non Open Market Buy 14,493 $10,000 2 Days Ago Recent Analyst Action: Vernon Bernardino, analyst at H.C. Wainwright, reiterates coverage on [Moleculin Biotech (MBRX)]( in the Healthcare sector with a Buy rating and a price target of $3 (1 week ago). Here are 3rd party ratings for [MBRX](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Top 29% (73 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Roblox]( Ticker: [RBLX]( Recent Price: $46.85 Average Analyst Price Target: $49.40 (-9.50%) Market Cap: $28.93B Role Transaction Description No. of Shares Amount Date Gen. Counsel & Secretary Informative Buy Options Exercised and fully kept 29,368 $99,851 3 Days Ago Recent Analyst Action: Andrew Uerkwitz, analyst at Jefferies, reiterates coverage on [Roblox (RBLX)]( in the Communication Services sector with a Buy rating and a price target of $51 (1 week ago). Here are 3rd party ratings for [RBLX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 24% (60 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The Biggest Drug Ever]( Morgan Stanley predicts it will become the biggest selling drug of all time. The Wall Street Journal calls it "King Kong"... Barron's says it will be a "blockbuster"... And The New York Post calls it "game-changing"... [Get the name of the drug here ]( --------------------------------------------------------------- [Greif Class A]( Ticker: [GEF]( Recent Price: $66.16 Average Analyst Price Target: $74.25 (12.23%) Market Cap: $3.14B Role Transaction Description No. of Shares Amount Date EVP & CFO Informative Buy Non Open Market Buy 700 $47,306 2 Days Ago Recent Analyst Action: Michael E., analyst at Stifel Nicolaus, reiterates coverage on [Greif Class A (GEF)]( in the Consumer Cyclical sector with a Buy rating and a price target of $88 (2 weeks ago). Here are 3rd party ratings for [GEF](: - TipRanks.com: Hold - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Strong Sell, Top 30% (76 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Southland Holdings]( Ticker: [SLND]( Recent Price: $5.07 Average Analyst Price Target: $7.50 (47.93%) Market Cap: $236.59M Role Transaction Description No. of Shares Amount Date President & CEO,Director, >10% Owner Informative Buy Non Open Market Buy 14,624 $75,503 3 Days Ago Director Informative Buy Non Open Market Buy 1,000 $5,130 3 Days Ago CO-COO AND EVP, >10% Owner Informative Buy Non Open Market Buy 7,222 $37,168 3 Days Ago Recent Analyst Action: Brent Thielman, analyst at D.A. Davidson, reiterates coverage on [Southland Holdings (SLND)]( in the Industrials sector with a Hold rating and a price target of $6 (1 month ago). Here are 3rd party ratings for [SLND](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Elon Musk May Have Just Changed Everything]( computing, 3D Printing and Gene-Editing... These are three of the most disruptive pieces of technology in recent times... But none of them compare to a project Elon Musk just released...[one that could soon mint the world's first trillionaire...]( --------------------------------------------------------------- And there you have it. To Your Financial Freedom, The Editor InsideTraderAlerts Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. [If you are not a human, click here.]( InsideTraderAlerts part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software